Skip to main content

Table 4 Outcomes of multivariate analysis to determine risk factors for adverse event of the GMA therapy

From: Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease in special situations: a multicentre cohort study

Variable

Model 1 (forced entry)

Model 2 (backward elimination*)

OR

95% CI

P value

OR

95% CI

P value

Patients who received corticosteroid

0.370

0.168–0.817

0.014

0.378

0.173–0.827

0.015

Number of concomitant immunosuppressant medications

0

Reference

     

1

2.815

1.161–6.824

0.022

2.724

1.131–6.561

0.025

2

3.559

1.252–10.112

0.017

3.335

1.187–9.374

0.022

≥ 3

12.879

3.303–50.225

< 0.001

11.764

3.091–44.77

< 0.001

Paediatric/adolescent patients (≤18 years)

2.601

1.034–6.542

0.042

2.075

0.926–4.648

0.076

Elderly patients (≥65 years)

1.307

0.611–2.796

0.490

   

Patients who received GMA retreatment

1.120

0.518–2.421

0.774

   

Patients with anaemia (haemoglobin < 10 g/dL)

2.124

1.088–4.146

0.027

2.019

1.054–3.867

0.034

Sex (female)

1.595

0.835–3.045

0.157

1.582

0.838–2.984

0.157

Type of IBD (UC)

0.506

0.196–1.308

0.160

0.519

0.204–1.322

0.169

Duration of disease (year)

1.015

0.978–1.054

0.434

   
  1. GMA granulocyte and monocyte adsorptive apheresis, IBD inflammatory bowel disease, UC ulcerative colitis, OR odds ratio, CI confidence interval
  2. *Variables with P > 0.2 were excluded via the backward elimination method